Generic Drug Competition
Generic drug competition plays a critical role in keeping a check healthcare spending in pharmaceuticals. Understanding which factors effect which factors influence the competitiveness of this sector is important for policy-makers. This session explores several such factors. The first paper considers generic entry decisions. It explores the oft-ignored first-stage decision in the two stage process that firms undertake before their product is on the market: the firm first decides to file an application and only later does it decide whether to exercise that option by marketing the product. The second paper considers when not exercising the option to market should be considered an anti-trust violation. The third paper considers the price effects of regulatory changes that reduce the number of competitors in markets for generic drugs.